DOCSLIB.ORG

Environmental Protection Agency § 725.422

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Environmental Protection Agency § 725.422 Environmental Protection Agency § 725.422 below in paragraphs (d)(2) through Sequence Source Toxin Name (d)(7) of this section, these comparable Bacillus anthracis Edema factor (Factors I II); toxin sequences, regardless of the orga- Lethal factor (Factors II III) nism from which they are derived, Bacillus cereus Enterotoxin (diarrheagenic must not be included in the introduced toxin, mouse lethal factor) genetic material. Bordetella pertussis Adenylate cyclase (Heat-la- (2) Sequences for protein synthesis in- bile factor); Pertussigen (pertussis toxin, islet acti- hibitor. vating factor, histamine sensitizing factor, Sequence Source Toxin Name lymphocytosis promoting factor) Corynebacterium diphtheriae Diphtheria toxin Clostridium botulinum C2 toxin & C. ulcerans Clostridium difficile Enterotoxin (toxin A) Pseudomonas aeruginosa Exotoxin A Clostridium perfringens Beta-toxin; Delta-toxin Shigella dysenteriae Shigella toxin (Shiga toxin, Shigella dysenteriae type I Escherichia coli & other Heat-labile enterotoxins (LT); toxin, Vero cell toxin) Enterobacteriaceae spp. Heat-stable enterotoxins Abrus precatorius, seeds Abrin (STa, ST1 subtypes ST1a Ricinus communis, seeds Ricin ST1b; also STb, STII) Legionella pneumophila Cytolysin (3) Sequences for neurotoxins. Vibrio cholerae & Vibrio Cholera toxin (choleragen) mimicus Sequence Source Toxin Name (6) Sequences that affect membrane Clostridium botulinum Neurotoxins A, B, C1, D, E, integrity. F, G (Botulinum toxins, botulinal toxins) Sequence Source Toxin Name Clostridium tetani Tetanus toxin (tetanospasmin) Clostridium bifermentans & Lecithinase Proteus mirabilis Neurotoxin other Clostridium spp Staphylococcus aureus Alpha toxin (alpha lysin) Clostridium perfringens Alpha-toxin (phospholipase Yersinia pestis Murine toxin C, lecithinase); Enterotoxin Snake toxins Corynebacterium pyogenes & Cytolysin (phospholipase C), Bungarus caeruleus Caeruleotoxin other Corynebacterium spp. Ovis toxin Bungarus multicinctus Beta-bungarotoxin (sphingomyelinase D) (phospholipase) Staphylococcus aureus Beta-lysin (beta toxin) Crotalus spp. Crotoxin (phospholipase) Dendroaspis viridis Neurotoxin (7) Sequences that are general Naja naja varieties Neurotoxin cytotoxins. Notechia scutatus Notexin (phospholipase) Oxyuranus scutellatus Taipoxin Sequence Source Toxin Name Invertebrate toxins Chironex fleckeri Neurotoxin Adenia digitata Modeccin Androctnus australis Neurotoxin Aeromonas hydrophila Aerolysin (beta-lysin, Centruroides sculpturatus Neurotoxin cytotoxic lysin) Clostridium difficile Cytotoxin (toxin B) (4) Sequences for oxygen labile Clostridium perfringens Beta-toxin; Epsilon-toxin; cytolysins. Kappa-toxin Escherichia coli & other Cytotoxin (Shiga-like toxin, Sequence Source Toxin Name Enterobacteriaceae spp. Vero cell toxin) Pseudomonas aeruginosa Proteases Bacillus alve Alveolysin Staphylococcus aureus Gamma lysin (Gamma toxin); Bacillus cereus Cereolysin Enterotoxins (SEA, SEB, Bacillus laterosporus Laterosporolysin SEC, SED SEE); Bacillus thuringiensis Thuringiolysin Pyrogenic exotoxins A B; Clostridium bifermentans Lysin Toxic shock syndrome tox- Clostridium botulinum Lysin ins (TSST-1) Clostridium caproicum Lysin Staphylococcus aureus & Leucocidin (leukocidin, Clostridium chauvoei Delta-toxin Pseudomonas aeruginosa cytotoxin) Clostridium histolyticum Epsilon-toxin Streptococcus pyogenes Streptolysin S (SLS); Clostridium novyi Gamma-toxin Erythrogenic toxins (scarlet Clostridium oedematiens Delta-toxin fever toxins, pyrogenic Clostridium perfringens Theta-toxin (Perfringolysin) exotoxins) Clostridium septicum Delta-toxin Yersinia enterocolitica Heat-stable enterotoxins (ST) Clostridium sordellii Lysin Clostridium tetani Tetanolysin Listeria monocytogenes Listeriolysin (A B) § 725.422 Physical containment and Streptococcus pneumoniae Pneumolysin control technologies. Streptococcus pyogene Streptolysin O (SLO) The manufacturer must meet all of (5) Sequences for toxins affecting mem- the following criteria for physical con- brane function. tainment and control technologies for 551 VerDate Aug<31>2005 14:36 Aug 06, 2007 Jkt 211171 PO 00000 Frm 00561 Fmt 8010 Sfmt 8010 Y:\SGML\211171.XXX 211171 rfrederick on PROD1PC67 with CFR § 725.424 40 CFR Ch. I (7–1–07 Edition) any facility in which the new micro- quirements of § 725.65 and maintains organism will be used for a Tier I ex- records for the initial and subsequent emption; these criteria also serve as uses of the new microorganism that guidance for a Tier II exemption. verify compliance with the following: (a) Use a structure that is designed (i) The certifications made in para- and operated to contain the new micro- graph (b) of this section. organism. (ii) All the eligibility criteria for the (b) Control access to the structure. Tier I exemption including the criteria (c) Provide written, published, and for the recipient microorganism, the implemented procedures for the safety introduced genetic material, the phys- of personnel and control of hygiene. ical containment and control tech- (d) Use inactivation procedures dem- nologies. onstrated and documented to be effec- (b) Certification. To be eligible for the tive against the new microorganism Tier I exemption under this subpart, contained in liquid and solid wastes the manufacturer or importer must prior to disposal of the wastes. The in- submit to EPA a document signed by a activation procedures must reduce via- responsible company official con- ble microbial populations by at least 6 taining the information listed in this logs in liquid and solid wastes. paragraph. (e) Use features known to be effective (1) Name and address of manufac- in minimizing viable microbial popu- turer or importer. lations in aerosols and exhaust gases (2) Date when manufacture or import released from the structure, and docu- is expected to begin. ment use of such features. (3) The identification (genus, species) (f) Use systems for controlling dis- of the recipient microorganism listed semination of the new microorganism in § 725.420 which is being used to create through other routes, and document the new microorganism which will be use of such features. used under the conditions of the Tier I (g) Have in place emergency clean-up exemption. procedures. (4) Certification of the following: (i) Compliance with the introduced § 725.424 Requirements for the Tier I genetic material criteria described in exemption. § 725.421. (a) Conditions of exemption. The manu- (ii) Compliance with the containment facture or import of a new microorga- requirements described in § 725.422, in- nism for commercial purposes is not cluding the provision in paragraph subject to review under this part if all (a)(3) of this section. of the following conditions are met for (5) The site of waste disposal and the all activities involving the new micro- type of permits for disposal, the permit organism: numbers and the institutions issuing (1) The recipient microorganism is the permits. listed in and meets any requirements (6) The certification statement re- specified in § 725.420. quired in § 725.25(b). Certification of (2) The introduced genetic material submission of test data is not required meets the criteria under § 725.421. for the Tier I exemption. (3) The physical containment and control technologies of any facility in § 725.426 Applicability of the Tier I ex- which the microorganism will be man- emption. ufactured, processed, or used meet the The Tier I exemption under § 725.424 criteria under § 725.422. applies only to a manufacturer or im- (4) The manufacturer or importer porter of a new microorganism that submits a certification described in certifies that the microorganism will paragraph (b) of this section to EPA at be used in all cases in compliance with least 10 days before commencing initial §§ 725.420, 725.421, and 725.422. manufacture or import of a new micro- organism derived from a recipient § 725.428 Requirements for the Tier II microorganism listed in § 725.420. exemption. (5) The manufacturer or importer The manufacturer or importer of a complies with the recordkeeping re- new microorganism for commercial 552 VerDate Aug<31>2005 14:36 Aug 06, 2007 Jkt 211171 PO 00000 Frm 00562 Fmt 8010 Sfmt 8010 Y:\SGML\211171.XXX 211171 rfrederick on PROD1PC67 with CFR.
Load more

Recommended publications
  • The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections
    toxins Review The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections Patience Shumba 1, Srikanth Mairpady Shambat 2 and Nikolai Siemens 1,* 1 Center for Functional Genomics of Microbes, Department of Molecular Genetics and Infection Biology, University of Greifswald, D-17489 Greifswald, Germany; [email protected] 2 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, CH-8091 Zurich, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +49-3834-420-5711 Received: 20 May 2019; Accepted: 10 June 2019; Published: 11 June 2019 Abstract: Necrotizing soft tissue infections (NSTIs) are critical clinical conditions characterized by extensive necrosis of any layer of the soft tissue and systemic toxicity. Group A streptococci (GAS) and Staphylococcus aureus are two major pathogens associated with monomicrobial NSTIs. In the tissue environment, both Gram-positive bacteria secrete a variety of molecules, including pore-forming exotoxins, superantigens, and proteases with cytolytic and immunomodulatory functions. The present review summarizes the current knowledge about streptococcal and staphylococcal toxins in NSTIs with a special focus on their contribution to disease progression, tissue pathology, and immune evasion strategies. Keywords: Streptococcus pyogenes; group A streptococcus; Staphylococcus aureus; skin infections; necrotizing soft tissue infections; pore-forming toxins; superantigens; immunomodulatory proteases; immune responses Key Contribution: Group A streptococcal and Staphylococcus aureus toxins manipulate host physiological and immunological responses to promote disease severity and progression. 1. Introduction Necrotizing soft tissue infections (NSTIs) are rare and represent a more severe rapidly progressing form of soft tissue infections that account for significant morbidity and mortality [1].
    [Show full text]
  • Medical Management of Biological Casualties Handbook
    USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES FORT DETRICK FREDERICK, MARYLAND Emergency Response Numbers National Response Center: 1-800-424-8802 or (for chem/bio hazards & terrorist events) 1-202-267-2675 National Domestic Preparedness Office: 1-202-324-9025 (for civilian use) Domestic Preparedness Chem/Bio Helpline: 1-410-436-4484 or (Edgewood Ops Center – for military use) DSN 584-4484 USAMRIID’s Emergency Response Line: 1-888-872-7443 CDC'S Emergency Response Line: 1-770-488-7100 Handbook Download Site An Adobe Acrobat Reader (pdf file) version of this handbook can be downloaded from the internet at the following url: http://www.usamriid.army.mil USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 Lead Editor Lt Col Jon B. Woods, MC, USAF Contributing Editors CAPT Robert G. Darling, MC, USN LTC Zygmunt F. Dembek, MS, USAR Lt Col Bridget K. Carr, MSC, USAF COL Ted J. Cieslak, MC, USA LCDR James V. Lawler, MC, USN MAJ Anthony C. Littrell, MC, USA LTC Mark G. Kortepeter, MC, USA LTC Nelson W. Rebert, MS, USA LTC Scott A. Stanek, MC, USA COL James W. Martin, MC, USA Comments and suggestions are appreciated and should be addressed to: Operational Medicine Department Attn: MCMR-UIM-O U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Fort Detrick, Maryland 21702-5011 PREFACE TO THE SIXTH EDITION The Medical Management of Biological Casualties Handbook, which has become affectionately known as the "Blue Book," has been enormously successful - far beyond our expectations.
    [Show full text]
  • TETANUS in ANIMALS — SUMMARY of KNOWLEDGE Malinovská, Z
    DOI: 10.2478/fv-2020-0027 FOLIA VETERINARIA, 64, 3: 54—60, 2020 TETANUS IN ANIMALS — SUMMARY OF KNOWLEDGE Malinovská, Z., Čonková, E., Váczi, P. Department of Pharmacology and Toxicology University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 041 81 Košice Slovakia [email protected] ABSTRACT the effects of the neurotoxin. The treatment is difficult with an unclear prognosis. Tetanus is a neurologic non-transmissible disease (often fatal) of humans and other animals with a world- Key words: animal; Clostridium tetani; toxin; spasm; wide occurrence. Clostridium tetani is the spore produc- treatment ing bacillus which causes the bacterial disease. In deep penetrating wounds the spores germinate and produce a toxin called tetanospasmin. The main characteristic sign INTRODUCTION of tetanus is a spastic paralysis. A diagnosis is usually based on the clinical signs because the detection in the Of the clostridial neurotoxins, botulinum neurotoxin wound and the cultivation of C. tetani is very difficult. and tetanus neurotoxin are the most potent toxins [15]. Between animal species there is considerable variabili- Their extraordinary toxicity is caused by neurospecificity ty in the susceptibility to the bacillus. The most sensi- and metalloprotease activity, which results in the paralysis. tive animal species to the neurotoxin are horses. Sheep Tetanus is potentially a fatal disease and in some countries and cattle are less sensitive and tetanus in these animal it is still very active. Tetanus is a traumatic clostridiosis, species are less common. Tetanus in cats and dogs are an infection in humans and other animals with worldwide rare and dogs are less sensitive than cats.
    [Show full text]
  • Report from the 26Th Meeting on Toxinology,“Bioengineering Of
    toxins Meeting Report Report from the 26th Meeting on Toxinology, “Bioengineering of Toxins”, Organized by the French Society of Toxinology (SFET) and Held in Paris, France, 4–5 December 2019 Pascale Marchot 1,* , Sylvie Diochot 2, Michel R. Popoff 3 and Evelyne Benoit 4 1 Laboratoire ‘Architecture et Fonction des Macromolécules Biologiques’, CNRS/Aix-Marseille Université, Faculté des Sciences-Campus Luminy, 13288 Marseille CEDEX 09, France 2 Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d’Azur, CNRS, Sophia Antipolis, 06550 Valbonne, France; [email protected] 3 Bacterial Toxins, Institut Pasteur, 75015 Paris, France; michel-robert.popoff@pasteur.fr 4 Service d’Ingénierie Moléculaire des Protéines (SIMOPRO), CEA de Saclay, Université Paris-Saclay, 91191 Gif-sur-Yvette, France; [email protected] * Correspondence: [email protected]; Tel.: +33-4-9182-5579 Received: 18 December 2019; Accepted: 27 December 2019; Published: 3 January 2020 1. Preface This 26th edition of the annual Meeting on Toxinology (RT26) of the SFET (http://sfet.asso.fr/ international) was held at the Institut Pasteur of Paris on 4–5 December 2019. The central theme selected for this meeting, “Bioengineering of Toxins”, gave rise to two thematic sessions: one on animal and plant toxins (one of our “core” themes), and a second one on bacterial toxins in honour of Dr. Michel R. Popoff (Institut Pasteur, Paris, France), both sessions being aimed at emphasizing the latest findings on their respective topics. Nine speakers from eight countries (Belgium, Denmark, France, Germany, Russia, Singapore, the United Kingdom, and the United States of America) were invited as international experts to present their work, and other researchers and students presented theirs through 23 shorter lectures and 27 posters.
    [Show full text]
  • Biosafety Manual 2017
    Biosafety Manual 2017 Revised 6/2017 Policy Statement It is the policy of Northern Arizona University (NAU) to provide a safe working environment. The primary responsibility for insuring safe conduct and conditions in the laboratory resides with the principal investigator. The Office of Biological Safety is committed to providing up-to-date information, training, and monitoring to the research and biomedical community concerning the safe conduct of biological, recombinant, and acute toxin research and the handling of biological materials in accordance with all pertinent local, state and federal regulations, guidelines, and laws. To that end, this manual is a resource, to be used in conjunction with the CDC and NIH guidelines, the NAU Select Agent Program, Biosafety in Microbiological and Biomedical Laboratories (BMBL), and other resource materials. Introduction This Biological Safety Manual is intended for use as a guidance document for researchers and clinicians who work with biological materials. It should be used in conjunction with the Laboratory-Specific Safety Manual, which provides more general safety information. These manuals describe policies and procedures that are required for the safe conduct of research at NAU. The NAU Personnel Policy on Safety 5.03 also provides guidance for safety in the workplace. Responsibilities In the academic research/teaching setting, the principal investigator (PI) is responsible for ensuring that all members of the laboratory are familiar with safe research practices. In the clinical laboratory setting, the faculty member who supervises the laboratory is responsible for safety practices. Lab managers, supervisors, technicians and others who provide supervisory roles in laboratories and clinical settings are responsible for overseeing the safety practices in laboratories and reporting any problems, accidents, and spills to the appropriate faculty member.
    [Show full text]
  • Immune Effector Mechanisms and Designer Vaccines Stewart Sell Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA
    EXPERT REVIEW OF VACCINES https://doi.org/10.1080/14760584.2019.1674144 REVIEW How vaccines work: immune effector mechanisms and designer vaccines Stewart Sell Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA ABSTRACT ARTICLE HISTORY Introduction: Three major advances have led to increase in length and quality of human life: Received 6 June 2019 increased food production, improved sanitation and induction of specific adaptive immune Accepted 25 September 2019 responses to infectious agents (vaccination). Which has had the most impact is subject to debate. KEYWORDS The number and variety of infections agents and the mechanisms that they have evolved to allow Vaccines; immune effector them to colonize humans remained mysterious and confusing until the last 50 years. Since then mechanisms; toxin science has developed complex and largely successful ways to immunize against many of these neutralization; receptor infections. blockade; anaphylactic Areas covered: Six specific immune defense mechanisms have been identified. neutralization, cytolytic, reactions; antibody- immune complex, anaphylactic, T-cytotoxicity, and delayed hypersensitivity. The role of each of these mediated cytolysis; immune immune effector mechanisms in immune responses induced by vaccination against specific infectious complex reactions; T-cell- mediated cytotoxicity; agents is the subject of this review. delayed hypersensitivity Expertopinion: In the past development of specific vaccines for infections agents was largely by trial and error. With an understanding of the natural history of an infection and the effective immune response to it, one can select the method of vaccination that will elicit the appropriate immune effector mechanisms (designer vaccines). These may act to prevent infection (prevention) or eliminate an established on ongoing infection (therapeutic).
    [Show full text]
  • Response of Cellular Innate Immunity to Cnidarian Pore-Forming Toxins
    Review Response of Cellular Innate Immunity to Cnidarian Pore-Forming Toxins Wei Yuen Yap 1 and Jung Shan Hwang 2,* 1 Department of Biological Sciences, School of Science and Technology, Sunway University, No. 5 Jalan Universiti, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia; [email protected] 2 Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, No. 5 Jalan Universiti, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia * Correspondence: [email protected]; Tel.: +603-7491-8622 (ext. 7414) Academic Editor: Jean-Marc Sabatier Received: 23 August 2018; Accepted: 28 September 2018; Published: 4 October 2018 Abstract: A group of stable, water-soluble and membrane-bound proteins constitute the pore forming toxins (PFTs) in cnidarians. They interact with membranes to physically alter the membrane structure and permeability, resulting in the formation of pores. These lesions on the plasma membrane causes an imbalance of cellular ionic gradients, resulting in swelling of the cell and eventually its rupture. Of all cnidarian PFTs, actinoporins are by far the best studied subgroup with established knowledge of their molecular structure and their mode of pore-forming action. However, the current view of necrotic action by actinoporins may not be the only mechanism that induces cell death since there is increasing evidence showing that pore-forming toxins can induce either necrosis or apoptosis in a cell-type, receptor and dose-dependent manner. In this review, we focus on the response of the cellular immune system to the cnidarian pore-forming toxins and the signaling pathways that might be involved in these cellular responses.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Hemolysin CB with Human C5a Receptors Γ Valentine Leukocidin
    Differential Interaction of the Staphylococcal Toxins Panton−Valentine Leukocidin and γ -Hemolysin CB with Human C5a Receptors This information is current as András N. Spaan, Ariën Schiepers, Carla J. C. de Haas, of October 1, 2021. Davy D. J. J. van Hooijdonk, Cédric Badiou, Hugues Contamin, François Vandenesch, Gérard Lina, Norma P. Gerard, Craig Gerard, Kok P. M. van Kessel, Thomas Henry and Jos A. G. van Strijp J Immunol 2015; 195:1034-1043; Prepublished online 19 June 2015; Downloaded from doi: 10.4049/jimmunol.1500604 http://www.jimmunol.org/content/195/3/1034 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2015/06/19/jimmunol.150060 Material 4.DCSupplemental References This article cites 46 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/195/3/1034.full#ref-list-1 Why The JI? Submit online. by guest on October 1, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc.
    [Show full text]
  • Panton-Valentine Leukocidin: a Review
    Reprinted from www.antimicrobe.org Panton-Valentine Leukocidin: A Review Marina Morgan F.R.C.Path. Venkata Meka, M.D. Panton-Valentine leukocidin (PVL) is a bi-component, pore-forming exotoxin produced by some strains of Staphylococcus aureus. Also termed a synergohymenotropic toxin (i.e. acts on membranes through the synergistic activity of 2 non-associated secretory proteins, component S and component F) (9), PVL toxin components assemble into heptamers on the neutrophil membrane, resulting in lytic pores and membrane damage. Injection of purified PVL induces histamine release from human basophilic granulocytes, enzymes (such as β-glucuronidase and lysozyme), chemotactic factors (such as leukotriene B4 and interleukin (IL-) 8), and oxygen metabolites from human neutrophilic granulocytes (5). Intradermal injection of purified PVL in rabbits causes severe inflammatory lesions with capillary dilation, chemotaxis, polymorphonuclear (PMN) infiltration, PMN karyorrhexis, and skin necrosis (17). PVL production is encoded by two contiguous and cotranscribed genes, lukS-PV and lukF-PV, found in a prophage segment integrated in the S. aureus chromosome (9). Traditionally some 2% of S. aureus produce PVL, however in certain groups in close contact with each other, such as military personnel, prisoners, and families of patients with infected skin lesions, skin to skin transmission is common resulting in a far higher carriage rates. Different PVL-positive S. aureus strains carry differing phage sequences, which can move into other strains methicillin and resistant, empowering them with PVl production genes (15). Many patients with PVL-positive necrotizing pneumonia have a preceding illness resembling influenza, with rigors pyrexia and myalgia. Expression of most S.
    [Show full text]
  • Impact of Bacterial Toxins in the Lungs
    toxins Review Impact of Bacterial Toxins in the Lungs 1,2,3, , 4,5, 3 2 Rudolf Lucas * y, Yalda Hadizamani y, Joyce Gonzales , Boris Gorshkov , Thomas Bodmer 6, Yves Berthiaume 7, Ueli Moehrlen 8, Hartmut Lode 9, Hanno Huwer 10, Martina Hudel 11, Mobarak Abu Mraheil 11, Haroldo Alfredo Flores Toque 1,2, 11 4,5,12,13, , Trinad Chakraborty and Jürg Hamacher * y 1 Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA; hfl[email protected] 2 Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA; [email protected] 3 Department of Medicine and Division of Pulmonary Critical Care Medicine, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA; [email protected] 4 Lungen-und Atmungsstiftung, Bern, 3012 Bern, Switzerland; [email protected] 5 Pneumology, Clinic for General Internal Medicine, Lindenhofspital Bern, 3012 Bern, Switzerland 6 Labormedizinisches Zentrum Dr. Risch, Waldeggstr. 37 CH-3097 Liebefeld, Switzerland; [email protected] 7 Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; [email protected] 8 Pediatric Surgery, University Children’s Hospital, Zürich, Steinwiesstrasse 75, CH-8032 Zürch, Switzerland; [email protected] 9 Insitut für klinische Pharmakologie, Charité, Universitätsklinikum Berlin, Reichsstrasse 2, D-14052 Berlin, Germany; [email protected] 10 Department of Cardiothoracic Surgery, Voelklingen Heart Center, 66333
    [Show full text]
  • Acute Specific Surgical Infection. Gas Gangrene. Anthrax. Diphtheria of Wounds
    Acute specific surgical infection. Tetanus. Gas gangrene. Anthrax. Diphtheria of wounds. Lecture for general surgery 2021 Chornaya I.A. Tetanus • Tetanus is an infectious disease • caused by contamination of wounds from the bacteria Clostridium tetani (an obligate anaerobic gram-positive bacillus,), or the spores they produce that live in the soil, and animal feces. • Picture of Clostridium tetani, with spore formation (oval forms at end of rods) Clostridium tetani Tetanus bacteria • Tetanus is caused by a bacterium belonging to the Clostridium genus, which thrives in the absence of oxygen. • It is found almost everywhere in the environment, most often in soil, dust, manure, and in the digestive tract of humans and animals. • The bacteria form spores, which are hard to kill and highly resistant to heat and many antiseptics. • Puncture wounds are the best entrance for the bacteria into your body Other tetanus-prone injuries include the following • frostbite, • surgery, • crush wound, • abscesses, • childbirth, • IV drug users (site of needle injection). • Wounds with devitalized (dead) tissue (for example, burns or crush injuries) or foreign bodies (debris in them) are most at risk of developing tetanus. • Tetanus may develop in people who are not immunized against it or in people who have failed to maintain adequate immunity with active booster doses of vaccine. Pathophysiology of Tetanus: • When a person gets injured, the wound or the cut becomes an environment that lacks oxygen. If the spores manage to find their way into the wound or the cut, they are able to germinate. After the spores of the bacterium germinate, they release a exotoxin, which is what causes all the ill- effects of the disease.
    [Show full text]